ArticleNPJ breast cancer2026
The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor status.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Apocrine morphology is a distinctive histopathological feature of breast cancer associated with unique clinical behavior, particularly in estrogen receptor (ER)-negative tumors. However, its molecular basis remains unclear and its relevance in ER-positive breast cancer has not been systematically examined. We performed an integrative analysis of breast cancer patients from the SEER database (n = 226,584) and The Cancer Genome Atlas (TCGA; n = 1017), incorporating clinicopathological, transcriptomic, and genomic data. Apocrine carcinoma was associated with favorable prognosis in ER-negative but worse survival in ER-positive breast cancer. Molecular and AR-related classifications did not fully recapitulate apocrine morphology. In ER-negative tumors, apocrine morphology correlated with lower proliferation and reduced predicted chemotherapy sensitivity. Conversely, in ER-positive tumors, apocrine morphology was associated with increased proliferation, enhanced immune-related signaling, and greater genomic instability. In conclusion, apocrine morphology represents an ER-dependent biological state with distinct prognostic and molecular implications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.